STAT5A and acute lymphoblastic leukemia: In BCR-ABL negative ALL primary cells, STAT5A siRNA decreased the cell viability by MTT assay in 3 out of 5 patient samples compared to their respective control groups (P2, P4 and P7) at both 30 nM and 60 nM.